The blockbuster pharmaceutical deal has had its share of detractors.
News & Analysis: Allergan
AbbVie's shares had an off year in 2019. Here's why.
Investors are cheering Allergan and jeering AbbVie after the announcement of a major acquisition.
Shares swoon after the FDA gives the thumbs down to its lead compound. Here's what investors need to know.
Mylan stepped up threats to Allergan's two largest revenue streams.
Allergan's shares fell off a cliff last year. Can it rebound in 2018?
Allergan's stock slips for the third straight month in October.
Allergan's stock fell in sympathy with Teva Pharmaceutical Industries in August, but it may now be a bargain as a result.
Shares respond positively to the announcement of upbeat data from a phase 3 study.
The drugmaker's stock took a dip in October over the raging drug pricing debate.
It's not every day you see a biotech go up by more than 700%.